nodes	percent_of_prediction	percent_of_DWPC	metapath
Aprepitant—CYP3A5—Sulfasalazine—Crohn's disease	0.0657	0.511	CbGbCtD
Aprepitant—CYP2C19—Prednisone—Crohn's disease	0.0424	0.33	CbGbCtD
Aprepitant—CYP3A4—Prednisone—Crohn's disease	0.0205	0.159	CbGbCtD
Aprepitant—TACR3—Peptide GPCRs—CCR9—Crohn's disease	0.0144	0.0448	CbGpPWpGaD
Aprepitant—TACR3—Peptide ligand-binding receptors—ACKR2—Crohn's disease	0.0103	0.0321	CbGpPWpGaD
Aprepitant—TACR3—G alpha (q) signalling events—MLN—Crohn's disease	0.00987	0.0308	CbGpPWpGaD
Aprepitant—TACR3—Peptide ligand-binding receptors—MLN—Crohn's disease	0.00975	0.0304	CbGpPWpGaD
Aprepitant—TACR3—Peptide GPCRs—CCR6—Crohn's disease	0.00952	0.0297	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—MLN—Crohn's disease	0.00883	0.0275	CbGpPWpGaD
Aprepitant—TACR1—Peptide GPCRs—CCR9—Crohn's disease	0.00702	0.0219	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—ACKR2—Crohn's disease	0.0069	0.0215	CbGpPWpGaD
Aprepitant—TACR3—Peptide ligand-binding receptors—CCR9—Crohn's disease	0.00676	0.0211	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—MLN—Crohn's disease	0.00654	0.0204	CbGpPWpGaD
Aprepitant—TACR3—G alpha (q) signalling events—GPR65—Crohn's disease	0.00636	0.0198	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—GPR65—Crohn's disease	0.00569	0.0177	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—ACKR2—Crohn's disease	0.00525	0.0164	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—CREM—Crohn's disease	0.0051	0.0159	CbGpPWpGaD
Aprepitant—TACR1—Peptide ligand-binding receptors—ACKR2—Crohn's disease	0.00502	0.0157	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—MLN—Crohn's disease	0.00498	0.0155	CbGpPWpGaD
Aprepitant—TACR1—G alpha (q) signalling events—MLN—Crohn's disease	0.00482	0.015	CbGpPWpGaD
Aprepitant—TACR1—Peptide ligand-binding receptors—MLN—Crohn's disease	0.00476	0.0148	CbGpPWpGaD
Aprepitant—TACR1—Peptide GPCRs—CCR6—Crohn's disease	0.00465	0.0145	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.00453	0.0141	CbGpPWpGaD
Aprepitant—TACR3—Peptide ligand-binding receptors—CCR6—Crohn's disease	0.00448	0.014	CbGpPWpGaD
Aprepitant—Oropharyngeal pain—Mesalazine—Crohn's disease	0.00434	0.00787	CcSEcCtD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—MLN—Crohn's disease	0.00431	0.0134	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.00421	0.0131	CbGpPWpGaD
Aprepitant—Blood bilirubin increased—Mesalazine—Crohn's disease	0.00417	0.00757	CcSEcCtD
Aprepitant—Musculoskeletal pain—Mesalazine—Crohn's disease	0.00399	0.00725	CcSEcCtD
Aprepitant—Epigastric discomfort—Prednisone—Crohn's disease	0.00397	0.0072	CcSEcCtD
Aprepitant—Stomatitis—Mercaptopurine—Crohn's disease	0.00396	0.00719	CcSEcCtD
Aprepitant—Phosphatase alkaline increased—Mesalazine—Crohn's disease	0.00394	0.00716	CcSEcCtD
Aprepitant—Neoplasm—Azathioprine—Crohn's disease	0.00391	0.00711	CcSEcCtD
Aprepitant—Eructation—Mesalazine—Crohn's disease	0.00387	0.00703	CcSEcCtD
Aprepitant—Candida infection—Mesalazine—Crohn's disease	0.00376	0.00683	CcSEcCtD
Aprepitant—Blood urea increased—Mesalazine—Crohn's disease	0.00372	0.00676	CcSEcCtD
Aprepitant—Febrile neutropenia—Prednisone—Crohn's disease	0.00347	0.0063	CcSEcCtD
Aprepitant—TACR3—GPCR ligand binding—CCR9—Crohn's disease	0.00345	0.0108	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ACKR2—Crohn's disease	0.00337	0.0105	CbGpPWpGaD
Aprepitant—TACR1—Peptide ligand-binding receptors—CCR9—Crohn's disease	0.0033	0.0103	CbGpPWpGaD
Aprepitant—Immune system disorder—Mercaptopurine—Crohn's disease	0.0033	0.00598	CcSEcCtD
Aprepitant—Blood alkaline phosphatase increased—Mesalazine—Crohn's disease	0.00329	0.00597	CcSEcCtD
Aprepitant—TACR3—G alpha (q) signalling events—RASGRP1—Crohn's disease	0.00329	0.0103	CbGpPWpGaD
Aprepitant—Photosensitivity—Mesalazine—Crohn's disease	0.00326	0.00592	CcSEcCtD
Aprepitant—Embolism—Prednisone—Crohn's disease	0.00325	0.0059	CcSEcCtD
Aprepitant—Alopecia—Mercaptopurine—Crohn's disease	0.00322	0.00585	CcSEcCtD
Aprepitant—TACR3—GPCR ligand binding—GPR65—Crohn's disease	0.00321	0.01	CbGpPWpGaD
Aprepitant—Disorientation—Mesalazine—Crohn's disease	0.0032	0.00581	CcSEcCtD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—MLN—Crohn's disease	0.00319	0.00996	CbGpPWpGaD
Aprepitant—Malnutrition—Mercaptopurine—Crohn's disease	0.00318	0.00577	CcSEcCtD
Aprepitant—TACR1—G alpha (q) signalling events—GPR65—Crohn's disease	0.00311	0.00969	CbGpPWpGaD
Aprepitant—Thirst—Mesalazine—Crohn's disease	0.00301	0.00546	CcSEcCtD
Aprepitant—Renal impairment—Mesalazine—Crohn's disease	0.00301	0.00546	CcSEcCtD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.003	0.00936	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—Crohn's disease	0.00294	0.00917	CbGpPWpGaD
Aprepitant—Anaemia—Mercaptopurine—Crohn's disease	0.00294	0.00533	CcSEcCtD
Aprepitant—Lethargy—Mesalazine—Crohn's disease	0.00292	0.0053	CcSEcCtD
Aprepitant—Osteoarthritis—Mesalazine—Crohn's disease	0.00286	0.0052	CcSEcCtD
Aprepitant—Toxic epidermal necrolysis—Azathioprine—Crohn's disease	0.00283	0.00514	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—MLN—Crohn's disease	0.00281	0.00877	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—GPR65—Crohn's disease	0.00278	0.00866	CbGpPWpGaD
Aprepitant—Arthralgia—Mercaptopurine—Crohn's disease	0.0027	0.00491	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—ACKR2—Crohn's disease	0.0027	0.0084	CbGpPWpGaD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.00269	0.00488	CcSEcCtD
Aprepitant—Blood creatinine increased—Mesalazine—Crohn's disease	0.00268	0.00487	CcSEcCtD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.00264	0.00824	CbGpPWpGaD
Aprepitant—Abdominal pain upper—Mesalazine—Crohn's disease	0.00261	0.00475	CcSEcCtD
Aprepitant—Abdominal discomfort—Azathioprine—Crohn's disease	0.0026	0.00473	CcSEcCtD
Aprepitant—Oedema—Mercaptopurine—Crohn's disease	0.00259	0.00471	CcSEcCtD
Aprepitant—Breast disorder—Mesalazine—Crohn's disease	0.00259	0.0047	CcSEcCtD
Aprepitant—Aspartate aminotransferase increased—Mesalazine—Crohn's disease	0.00258	0.00468	CcSEcCtD
Aprepitant—Cramp muscle—Mesalazine—Crohn's disease	0.00258	0.00468	CcSEcCtD
Aprepitant—Glycosuria—Prednisone—Crohn's disease	0.00258	0.00468	CcSEcCtD
Aprepitant—TACR1—GPCR ligand binding—ACKR2—Crohn's disease	0.00256	0.008	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—MLN—Crohn's disease	0.00256	0.00797	CbGpPWpGaD
Aprepitant—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.00254	0.00461	CcSEcCtD
Aprepitant—Gastritis—Mesalazine—Crohn's disease	0.00253	0.0046	CcSEcCtD
Aprepitant—Alanine aminotransferase increased—Mesalazine—Crohn's disease	0.00252	0.00458	CcSEcCtD
Aprepitant—Skin disorder—Mercaptopurine—Crohn's disease	0.00252	0.00457	CcSEcCtD
Aprepitant—Abdominal distension—Mesalazine—Crohn's disease	0.00249	0.00452	CcSEcCtD
Aprepitant—Dysphagia—Mesalazine—Crohn's disease	0.00247	0.00449	CcSEcCtD
Aprepitant—Anorexia—Mercaptopurine—Crohn's disease	0.00247	0.00449	CcSEcCtD
Aprepitant—Pneumonia—Azathioprine—Crohn's disease	0.00244	0.00442	CcSEcCtD
Aprepitant—TACR1—GPCR ligand binding—MLN—Crohn's disease	0.00243	0.00758	CbGpPWpGaD
Aprepitant—Infestation—Azathioprine—Crohn's disease	0.00242	0.0044	CcSEcCtD
Aprepitant—Infestation NOS—Azathioprine—Crohn's disease	0.00242	0.0044	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.0024	0.00436	CcSEcCtD
Aprepitant—Abdominal discomfort—Mesalazine—Crohn's disease	0.00237	0.00431	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.00236	0.00429	CcSEcCtD
Aprepitant—Dysuria—Mesalazine—Crohn's disease	0.00231	0.0042	CcSEcCtD
Aprepitant—Neutropenia—Mesalazine—Crohn's disease	0.00231	0.0042	CcSEcCtD
Aprepitant—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.0023	0.00417	CcSEcCtD
Aprepitant—TACR3—GPCR ligand binding—CCR6—Crohn's disease	0.00229	0.00713	CbGpPWpGaD
Aprepitant—Pollakiuria—Mesalazine—Crohn's disease	0.00229	0.00415	CcSEcCtD
Aprepitant—Photosensitivity reaction—Mesalazine—Crohn's disease	0.00226	0.0041	CcSEcCtD
Aprepitant—Decreased appetite—Mercaptopurine—Crohn's disease	0.00225	0.00409	CcSEcCtD
Aprepitant—Weight increased—Mesalazine—Crohn's disease	0.00225	0.00409	CcSEcCtD
Aprepitant—Weight decreased—Mesalazine—Crohn's disease	0.00224	0.00406	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.00224	0.00406	CcSEcCtD
Aprepitant—Pneumonia—Mesalazine—Crohn's disease	0.00222	0.00403	CcSEcCtD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.00221	0.0069	CbGpPWpGaD
Aprepitant—Infestation NOS—Mesalazine—Crohn's disease	0.00221	0.004	CcSEcCtD
Aprepitant—Infestation—Mesalazine—Crohn's disease	0.00221	0.004	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.00219	0.00397	CcSEcCtD
Aprepitant—TACR1—Peptide ligand-binding receptors—CCR6—Crohn's disease	0.00219	0.00682	CbGpPWpGaD
Aprepitant—Renal failure—Mesalazine—Crohn's disease	0.00217	0.00394	CcSEcCtD
Aprepitant—Neuropathy peripheral—Mesalazine—Crohn's disease	0.00216	0.00393	CcSEcCtD
Aprepitant—Stomatitis—Mesalazine—Crohn's disease	0.00215	0.0039	CcSEcCtD
Aprepitant—Conjunctivitis—Mesalazine—Crohn's disease	0.00214	0.00389	CcSEcCtD
Aprepitant—Urinary tract infection—Mesalazine—Crohn's disease	0.00214	0.00389	CcSEcCtD
Aprepitant—Haematuria—Mesalazine—Crohn's disease	0.0021	0.00382	CcSEcCtD
Aprepitant—Hiccups—Prednisone—Crohn's disease	0.00209	0.00379	CcSEcCtD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.00206	0.00642	CbGpPWpGaD
Aprepitant—Erythema multiforme—Azathioprine—Crohn's disease	0.00206	0.00373	CcSEcCtD
Aprepitant—Body temperature increased—Mercaptopurine—Crohn's disease	0.00205	0.00372	CcSEcCtD
Aprepitant—TACR3—GPCR ligand binding—PTGER4—Crohn's disease	0.00201	0.00628	CbGpPWpGaD
Aprepitant—Pharyngitis—Mesalazine—Crohn's disease	0.00197	0.00357	CcSEcCtD
Aprepitant—Immune system disorder—Azathioprine—Crohn's disease	0.00196	0.00357	CcSEcCtD
Aprepitant—Mediastinal disorder—Azathioprine—Crohn's disease	0.00196	0.00356	CcSEcCtD
Aprepitant—Urinary tract disorder—Mesalazine—Crohn's disease	0.00196	0.00355	CcSEcCtD
Aprepitant—Chills—Azathioprine—Crohn's disease	0.00195	0.00354	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—CCR9—Crohn's disease	0.00195	0.00608	CbGpPWpGaD
Aprepitant—Connective tissue disorder—Mesalazine—Crohn's disease	0.00195	0.00353	CcSEcCtD
Aprepitant—Urethral disorder—Mesalazine—Crohn's disease	0.00194	0.00352	CcSEcCtD
Aprepitant—Alopecia—Azathioprine—Crohn's disease	0.00192	0.00349	CcSEcCtD
Aprepitant—Hypersensitivity—Mercaptopurine—Crohn's disease	0.00191	0.00347	CcSEcCtD
Aprepitant—Erythema multiforme—Mesalazine—Crohn's disease	0.00187	0.0034	CcSEcCtD
Aprepitant—Eye disorder—Mesalazine—Crohn's disease	0.00185	0.00336	CcSEcCtD
Aprepitant—Tinnitus—Mesalazine—Crohn's disease	0.00185	0.00335	CcSEcCtD
Aprepitant—Cardiac disorder—Mesalazine—Crohn's disease	0.00184	0.00334	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—GPR65—Crohn's disease	0.00181	0.00565	CbGpPWpGaD
Aprepitant—Angiopathy—Mesalazine—Crohn's disease	0.0018	0.00326	CcSEcCtD
Aprepitant—Euphoric mood—Prednisone—Crohn's disease	0.00179	0.00325	CcSEcCtD
Aprepitant—Immune system disorder—Mesalazine—Crohn's disease	0.00179	0.00325	CcSEcCtD
Aprepitant—Mediastinal disorder—Mesalazine—Crohn's disease	0.00178	0.00324	CcSEcCtD
Aprepitant—Chills—Mesalazine—Crohn's disease	0.00178	0.00323	CcSEcCtD
Aprepitant—Diarrhoea—Mercaptopurine—Crohn's disease	0.00177	0.00322	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—CCR9—Crohn's disease	0.00177	0.00552	CbGpPWpGaD
Aprepitant—Ill-defined disorder—Azathioprine—Crohn's disease	0.00176	0.00319	CcSEcCtD
Aprepitant—Alopecia—Mesalazine—Crohn's disease	0.00175	0.00318	CcSEcCtD
Aprepitant—Thrombophlebitis—Prednisone—Crohn's disease	0.00175	0.00318	CcSEcCtD
Aprepitant—Anaemia—Azathioprine—Crohn's disease	0.00175	0.00318	CcSEcCtD
Aprepitant—Diabetes mellitus—Prednisone—Crohn's disease	0.00174	0.00316	CcSEcCtD
Aprepitant—Mental disorder—Mesalazine—Crohn's disease	0.00173	0.00315	CcSEcCtD
Aprepitant—Erythema—Mesalazine—Crohn's disease	0.00172	0.00313	CcSEcCtD
Aprepitant—Malaise—Azathioprine—Crohn's disease	0.00171	0.0031	CcSEcCtD
Aprepitant—Flatulence—Mesalazine—Crohn's disease	0.0017	0.00308	CcSEcCtD
Aprepitant—Dysgeusia—Mesalazine—Crohn's disease	0.00169	0.00306	CcSEcCtD
Aprepitant—TACR1—GPCR ligand binding—CCR9—Crohn's disease	0.00169	0.00526	CbGpPWpGaD
Aprepitant—Back pain—Mesalazine—Crohn's disease	0.00167	0.00303	CcSEcCtD
Aprepitant—Muscle spasms—Mesalazine—Crohn's disease	0.00166	0.00301	CcSEcCtD
Aprepitant—Vomiting—Mercaptopurine—Crohn's disease	0.00165	0.00299	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—GPR65—Crohn's disease	0.00165	0.00513	CbGpPWpGaD
Aprepitant—Rash—Mercaptopurine—Crohn's disease	0.00163	0.00297	CcSEcCtD
Aprepitant—Dermatitis—Mercaptopurine—Crohn's disease	0.00163	0.00296	CcSEcCtD
Aprepitant—Tremor—Mesalazine—Crohn's disease	0.00161	0.00293	CcSEcCtD
Aprepitant—Arthralgia—Azathioprine—Crohn's disease	0.00161	0.00293	CcSEcCtD
Aprepitant—Myalgia—Azathioprine—Crohn's disease	0.00161	0.00293	CcSEcCtD
Aprepitant—TACR1—G alpha (q) signalling events—RASGRP1—Crohn's disease	0.00161	0.00501	CbGpPWpGaD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.0016	0.0029	CcSEcCtD
Aprepitant—Ill-defined disorder—Mesalazine—Crohn's disease	0.0016	0.0029	CcSEcCtD
Aprepitant—Anaemia—Mesalazine—Crohn's disease	0.00159	0.00289	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—ACKR2—Crohn's disease	0.00159	0.00496	CbGpPWpGaD
Aprepitant—Discomfort—Azathioprine—Crohn's disease	0.00159	0.00289	CcSEcCtD
Aprepitant—CYP2C19—Arachidonic acid metabolism—GPX4—Crohn's disease	0.00158	0.00492	CbGpPWpGaD
Aprepitant—Angioedema—Mesalazine—Crohn's disease	0.00158	0.00286	CcSEcCtD
Aprepitant—TACR1—GPCR ligand binding—GPR65—Crohn's disease	0.00157	0.00489	CbGpPWpGaD
Aprepitant—Malaise—Mesalazine—Crohn's disease	0.00155	0.00282	CcSEcCtD
Aprepitant—Syncope—Mesalazine—Crohn's disease	0.00155	0.00281	CcSEcCtD
Aprepitant—Lethargy—Prednisone—Crohn's disease	0.00155	0.00281	CcSEcCtD
Aprepitant—Nausea—Mercaptopurine—Crohn's disease	0.00154	0.0028	CcSEcCtD
Aprepitant—Infection—Azathioprine—Crohn's disease	0.00153	0.00279	CcSEcCtD
Aprepitant—Palpitations—Mesalazine—Crohn's disease	0.00152	0.00277	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—TLR4—Crohn's disease	0.00152	0.00474	CbGpPWpGaD
Aprepitant—Loss of consciousness—Mesalazine—Crohn's disease	0.00151	0.00275	CcSEcCtD
Aprepitant—Osteoarthritis—Prednisone—Crohn's disease	0.00151	0.00275	CcSEcCtD
Aprepitant—Thrombocytopenia—Azathioprine—Crohn's disease	0.00151	0.00275	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—MLN—Crohn's disease	0.00151	0.00471	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—IL10—Crohn's disease	0.00151	0.0047	CbGpPWpGaD
Aprepitant—Cough—Mesalazine—Crohn's disease	0.0015	0.00273	CcSEcCtD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—Crohn's disease	0.0015	0.00468	CbGpPWpGaD
Aprepitant—Skin disorder—Azathioprine—Crohn's disease	0.0015	0.00272	CcSEcCtD
Aprepitant—Hypertension—Mesalazine—Crohn's disease	0.00149	0.0027	CcSEcCtD
Aprepitant—Myalgia—Mesalazine—Crohn's disease	0.00147	0.00266	CcSEcCtD
Aprepitant—Chest pain—Mesalazine—Crohn's disease	0.00147	0.00266	CcSEcCtD
Aprepitant—Arthralgia—Mesalazine—Crohn's disease	0.00147	0.00266	CcSEcCtD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.00147	0.00457	CbGpPWpGaD
Aprepitant—Anxiety—Mesalazine—Crohn's disease	0.00146	0.00266	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.00146	0.00265	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—ICAM1—Crohn's disease	0.00146	0.00454	CbGpPWpGaD
Aprepitant—Discomfort—Mesalazine—Crohn's disease	0.00145	0.00263	CcSEcCtD
Aprepitant—Hypotension—Azathioprine—Crohn's disease	0.00144	0.00262	CcSEcCtD
Aprepitant—TACR3—Peptide ligand-binding receptors—CXCL8—Crohn's disease	0.00144	0.0045	CbGpPWpGaD
Aprepitant—CYP2C9—Arachidonic acid metabolism—GPX4—Crohn's disease	0.00144	0.00448	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—Crohn's disease	0.00144	0.00448	CbGpPWpGaD
Aprepitant—Dry mouth—Mesalazine—Crohn's disease	0.00144	0.00261	CcSEcCtD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—Crohn's disease	0.00143	0.00446	CbGpPWpGaD
Aprepitant—Confusional state—Mesalazine—Crohn's disease	0.00142	0.00258	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.00141	0.00255	CcSEcCtD
Aprepitant—Anaphylactic shock—Mesalazine—Crohn's disease	0.00141	0.00255	CcSEcCtD
Aprepitant—Oedema—Mesalazine—Crohn's disease	0.00141	0.00255	CcSEcCtD
Aprepitant—Infection—Mesalazine—Crohn's disease	0.0014	0.00254	CcSEcCtD
Aprepitant—Shock—Mesalazine—Crohn's disease	0.00138	0.00251	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—TAGAP—Crohn's disease	0.00138	0.0043	CbGpPWpGaD
Aprepitant—Nervous system disorder—Mesalazine—Crohn's disease	0.00138	0.0025	CcSEcCtD
Aprepitant—Hypokalaemia—Prednisone—Crohn's disease	0.00138	0.0025	CcSEcCtD
Aprepitant—Thrombocytopenia—Mesalazine—Crohn's disease	0.00138	0.0025	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—MLN—Crohn's disease	0.00137	0.00428	CbGpPWpGaD
Aprepitant—Tachycardia—Mesalazine—Crohn's disease	0.00137	0.00249	CcSEcCtD
Aprepitant—Skin disorder—Mesalazine—Crohn's disease	0.00137	0.00248	CcSEcCtD
Aprepitant—Hyperhidrosis—Mesalazine—Crohn's disease	0.00136	0.00247	CcSEcCtD
Aprepitant—Anorexia—Mesalazine—Crohn's disease	0.00134	0.00243	CcSEcCtD
Aprepitant—Muscular weakness—Prednisone—Crohn's disease	0.00134	0.00243	CcSEcCtD
Aprepitant—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.00134	0.00243	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.00133	0.00242	CcSEcCtD
Aprepitant—Abdominal distension—Prednisone—Crohn's disease	0.00132	0.00239	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—ACKR2—Crohn's disease	0.00132	0.0041	CbGpPWpGaD
Aprepitant—Hypotension—Mesalazine—Crohn's disease	0.00131	0.00239	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—CCR6—Crohn's disease	0.00129	0.00403	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.00129	0.00402	CbGpPWpGaD
Aprepitant—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.00128	0.00233	CcSEcCtD
Aprepitant—Sweating increased—Prednisone—Crohn's disease	0.00127	0.00231	CcSEcCtD
Aprepitant—Feeling abnormal—Azathioprine—Crohn's disease	0.00127	0.00231	CcSEcCtD
Aprepitant—Insomnia—Mesalazine—Crohn's disease	0.00127	0.00231	CcSEcCtD
Aprepitant—Paraesthesia—Mesalazine—Crohn's disease	0.00126	0.00229	CcSEcCtD
Aprepitant—Gastrointestinal pain—Azathioprine—Crohn's disease	0.00126	0.00229	CcSEcCtD
Aprepitant—Dyspnoea—Mesalazine—Crohn's disease	0.00125	0.00228	CcSEcCtD
Aprepitant—Somnolence—Mesalazine—Crohn's disease	0.00125	0.00227	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—MLN—Crohn's disease	0.00125	0.00389	CbGpPWpGaD
Aprepitant—Dyspepsia—Mesalazine—Crohn's disease	0.00124	0.00225	CcSEcCtD
Aprepitant—CYP1A2—Arachidonic acid metabolism—GPX4—Crohn's disease	0.00123	0.00383	CbGpPWpGaD
Aprepitant—Neutropenia—Prednisone—Crohn's disease	0.00122	0.00222	CcSEcCtD
Aprepitant—Decreased appetite—Mesalazine—Crohn's disease	0.00122	0.00222	CcSEcCtD
Aprepitant—Abdominal pain—Azathioprine—Crohn's disease	0.00122	0.00222	CcSEcCtD
Aprepitant—Body temperature increased—Azathioprine—Crohn's disease	0.00122	0.00222	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.00121	0.00221	CcSEcCtD
Aprepitant—Fatigue—Mesalazine—Crohn's disease	0.00121	0.0022	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—RSPO3—Crohn's disease	0.00121	0.00376	CbGpPWpGaD
Aprepitant—Constipation—Mesalazine—Crohn's disease	0.0012	0.00218	CcSEcCtD
Aprepitant—Pain—Mesalazine—Crohn's disease	0.0012	0.00218	CcSEcCtD
Aprepitant—Weight increased—Prednisone—Crohn's disease	0.00119	0.00216	CcSEcCtD
Aprepitant—Weight decreased—Prednisone—Crohn's disease	0.00118	0.00215	CcSEcCtD
Aprepitant—Hyperglycaemia—Prednisone—Crohn's disease	0.00118	0.00214	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—CCR6—Crohn's disease	0.00117	0.00366	CbGpPWpGaD
Aprepitant—Feeling abnormal—Mesalazine—Crohn's disease	0.00116	0.0021	CcSEcCtD
Aprepitant—Acute coronary syndrome—Prednisone—Crohn's disease	0.00115	0.00209	CcSEcCtD
Aprepitant—Gastrointestinal pain—Mesalazine—Crohn's disease	0.00115	0.00209	CcSEcCtD
Aprepitant—Neuropathy peripheral—Prednisone—Crohn's disease	0.00114	0.00208	CcSEcCtD
Aprepitant—Myocardial infarction—Prednisone—Crohn's disease	0.00114	0.00208	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—SEL1L—Crohn's disease	0.00114	0.00357	CbGpPWpGaD
Aprepitant—Hypersensitivity—Azathioprine—Crohn's disease	0.00114	0.00207	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—PTGER4—Crohn's disease	0.00114	0.00355	CbGpPWpGaD
Aprepitant—Urticaria—Mesalazine—Crohn's disease	0.00112	0.00203	CcSEcCtD
Aprepitant—TACR1—GPCR ligand binding—CCR6—Crohn's disease	0.00112	0.00348	CbGpPWpGaD
Aprepitant—Abdominal pain—Mesalazine—Crohn's disease	0.00111	0.00202	CcSEcCtD
Aprepitant—Body temperature increased—Mesalazine—Crohn's disease	0.00111	0.00202	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—IFNG—Crohn's disease	0.00111	0.00346	CbGpPWpGaD
Aprepitant—Bradycardia—Prednisone—Crohn's disease	0.00107	0.00194	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—PTGS2—Crohn's disease	0.00106	0.00332	CbGpPWpGaD
Aprepitant—Diarrhoea—Azathioprine—Crohn's disease	0.00106	0.00192	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—CCR9—Crohn's disease	0.00105	0.00326	CbGpPWpGaD
Aprepitant—Hallucination—Prednisone—Crohn's disease	0.00104	0.00189	CcSEcCtD
Aprepitant—Hypersensitivity—Mesalazine—Crohn's disease	0.00104	0.00188	CcSEcCtD
Aprepitant—CYP3A7—Metapathway biotransformation—GPX4—Crohn's disease	0.00104	0.00323	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—PTGER4—Crohn's disease	0.00103	0.00322	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—CXCL8—Crohn's disease	0.00103	0.00322	CbGpPWpGaD
Aprepitant—Connective tissue disorder—Prednisone—Crohn's disease	0.00103	0.00187	CcSEcCtD
Aprepitant—Dizziness—Azathioprine—Crohn's disease	0.00102	0.00185	CcSEcCtD
Aprepitant—Asthenia—Mesalazine—Crohn's disease	0.00101	0.00183	CcSEcCtD
Aprepitant—Pruritus—Mesalazine—Crohn's disease	0.000995	0.00181	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—IL1B—Crohn's disease	0.000989	0.00308	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—PTGER4—Crohn's disease	0.000983	0.00307	CbGpPWpGaD
Aprepitant—Vomiting—Azathioprine—Crohn's disease	0.000982	0.00178	CcSEcCtD
Aprepitant—Eye disorder—Prednisone—Crohn's disease	0.000979	0.00178	CcSEcCtD
Aprepitant—Rash—Azathioprine—Crohn's disease	0.000974	0.00177	CcSEcCtD
Aprepitant—Dermatitis—Azathioprine—Crohn's disease	0.000973	0.00177	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—GPR65—Crohn's disease	0.000973	0.00303	CbGpPWpGaD
Aprepitant—Flushing—Prednisone—Crohn's disease	0.000972	0.00177	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—IL3—Crohn's disease	0.000969	0.00302	CbGpPWpGaD
Aprepitant—Headache—Azathioprine—Crohn's disease	0.000968	0.00176	CcSEcCtD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000967	0.00302	CbGpPWpGaD
Aprepitant—Diarrhoea—Mesalazine—Crohn's disease	0.000963	0.00175	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—CCR9—Crohn's disease	0.000952	0.00297	CbGpPWpGaD
Aprepitant—Angiopathy—Prednisone—Crohn's disease	0.000951	0.00173	CcSEcCtD
Aprepitant—Immune system disorder—Prednisone—Crohn's disease	0.000946	0.00172	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000937	0.00292	CbGpPWpGaD
Aprepitant—Dizziness—Mesalazine—Crohn's disease	0.00093	0.00169	CcSEcCtD
Aprepitant—Alopecia—Prednisone—Crohn's disease	0.000926	0.00168	CcSEcCtD
Aprepitant—Mental disorder—Prednisone—Crohn's disease	0.000918	0.00167	CcSEcCtD
Aprepitant—Nausea—Azathioprine—Crohn's disease	0.000917	0.00167	CcSEcCtD
Aprepitant—Malnutrition—Prednisone—Crohn's disease	0.000912	0.00166	CcSEcCtD
Aprepitant—Erythema—Prednisone—Crohn's disease	0.000912	0.00166	CcSEcCtD
Aprepitant—Vomiting—Mesalazine—Crohn's disease	0.000894	0.00162	CcSEcCtD
Aprepitant—Rash—Mesalazine—Crohn's disease	0.000887	0.00161	CcSEcCtD
Aprepitant—Dermatitis—Mesalazine—Crohn's disease	0.000886	0.00161	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—GPR65—Crohn's disease	0.000885	0.00276	CbGpPWpGaD
Aprepitant—Headache—Mesalazine—Crohn's disease	0.000881	0.0016	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—IL3—Crohn's disease	0.00088	0.00274	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CCR9—Crohn's disease	0.000865	0.0027	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—Crohn's disease	0.000857	0.00267	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—RASGRP1—Crohn's disease	0.000851	0.00265	CbGpPWpGaD
Aprepitant—Ill-defined disorder—Prednisone—Crohn's disease	0.000846	0.00154	CcSEcCtD
Aprepitant—Anaemia—Prednisone—Crohn's disease	0.000843	0.00153	CcSEcCtD
Aprepitant—Nausea—Mesalazine—Crohn's disease	0.000836	0.00152	CcSEcCtD
Aprepitant—Angioedema—Prednisone—Crohn's disease	0.000833	0.00151	CcSEcCtD
Aprepitant—TACR1—SIDS Susceptibility Pathways—CXCL8—Crohn's disease	0.000825	0.00257	CbGpPWpGaD
Aprepitant—Malaise—Prednisone—Crohn's disease	0.000822	0.00149	CcSEcCtD
Aprepitant—Syncope—Prednisone—Crohn's disease	0.000818	0.00148	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—GPR65—Crohn's disease	0.000804	0.00251	CbGpPWpGaD
Aprepitant—Loss of consciousness—Prednisone—Crohn's disease	0.000802	0.00146	CcSEcCtD
Aprepitant—TACR1—SIDS Susceptibility Pathways—IL1B—Crohn's disease	0.000791	0.00247	CbGpPWpGaD
Aprepitant—Convulsion—Prednisone—Crohn's disease	0.00079	0.00143	CcSEcCtD
Aprepitant—Hypertension—Prednisone—Crohn's disease	0.000787	0.00143	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—ACKR2—Crohn's disease	0.000778	0.00242	CbGpPWpGaD
Aprepitant—Myalgia—Prednisone—Crohn's disease	0.000776	0.00141	CcSEcCtD
Aprepitant—Arthralgia—Prednisone—Crohn's disease	0.000776	0.00141	CcSEcCtD
Aprepitant—Anxiety—Prednisone—Crohn's disease	0.000774	0.0014	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000771	0.0014	CcSEcCtD
Aprepitant—Discomfort—Prednisone—Crohn's disease	0.000767	0.00139	CcSEcCtD
Aprepitant—CYP1A2—Estrogen Receptor Pathway—STAT3—Crohn's disease	0.000757	0.00236	CbGpPWpGaD
Aprepitant—CYP3A5—Metapathway biotransformation—GPX4—Crohn's disease	0.000749	0.00233	CbGpPWpGaD
Aprepitant—Oedema—Prednisone—Crohn's disease	0.000744	0.00135	CcSEcCtD
Aprepitant—Anaphylactic shock—Prednisone—Crohn's disease	0.000744	0.00135	CcSEcCtD
Aprepitant—Infection—Prednisone—Crohn's disease	0.000739	0.00134	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—MLN—Crohn's disease	0.000737	0.0023	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—CXCL8—Crohn's disease	0.000737	0.0023	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	0.000734	0.00229	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—Crohn's disease	0.000733	0.00229	CbGpPWpGaD
Aprepitant—Shock—Prednisone—Crohn's disease	0.000732	0.00133	CcSEcCtD
Aprepitant—Nervous system disorder—Prednisone—Crohn's disease	0.00073	0.00133	CcSEcCtD
Aprepitant—Tachycardia—Prednisone—Crohn's disease	0.000726	0.00132	CcSEcCtD
Aprepitant—Skin disorder—Prednisone—Crohn's disease	0.000723	0.00131	CcSEcCtD
Aprepitant—Hyperhidrosis—Prednisone—Crohn's disease	0.00072	0.00131	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—TNF—Crohn's disease	0.000718	0.00224	CbGpPWpGaD
Aprepitant—Anorexia—Prednisone—Crohn's disease	0.000709	0.00129	CcSEcCtD
Aprepitant—TACR1—Peptide ligand-binding receptors—CXCL8—Crohn's disease	0.000704	0.0022	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—Crohn's disease	0.000699	0.00218	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CCR6—Crohn's disease	0.000693	0.00216	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—IL2RA—Crohn's disease	0.000679	0.00212	CbGpPWpGaD
Aprepitant—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000678	0.00123	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—TAGAP—Crohn's disease	0.000674	0.0021	CbGpPWpGaD
Aprepitant—Insomnia—Prednisone—Crohn's disease	0.000673	0.00122	CcSEcCtD
Aprepitant—Paraesthesia—Prednisone—Crohn's disease	0.000668	0.00121	CcSEcCtD
Aprepitant—Dyspepsia—Prednisone—Crohn's disease	0.000655	0.00119	CcSEcCtD
Aprepitant—Decreased appetite—Prednisone—Crohn's disease	0.000647	0.00117	CcSEcCtD
Aprepitant—Fatigue—Prednisone—Crohn's disease	0.000642	0.00117	CcSEcCtD
Aprepitant—Constipation—Prednisone—Crohn's disease	0.000636	0.00116	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—CCR6—Crohn's disease	0.000631	0.00197	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—RBX1—Crohn's disease	0.000627	0.00195	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—IL2RA—Crohn's disease	0.000616	0.00192	CbGpPWpGaD
Aprepitant—Feeling abnormal—Prednisone—Crohn's disease	0.000613	0.00111	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—PTGER4—Crohn's disease	0.00061	0.0019	CbGpPWpGaD
Aprepitant—Gastrointestinal pain—Prednisone—Crohn's disease	0.000609	0.00111	CcSEcCtD
Aprepitant—Urticaria—Prednisone—Crohn's disease	0.000591	0.00107	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—RSPO3—Crohn's disease	0.000589	0.00184	CbGpPWpGaD
Aprepitant—Abdominal pain—Prednisone—Crohn's disease	0.000588	0.00107	CcSEcCtD
Aprepitant—Body temperature increased—Prednisone—Crohn's disease	0.000588	0.00107	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—IL6—Crohn's disease	0.000579	0.00181	CbGpPWpGaD
Aprepitant—CYP2C19—Metapathway biotransformation—GPX4—Crohn's disease	0.000579	0.0018	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—TNF—Crohn's disease	0.000574	0.00179	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CCR6—Crohn's disease	0.000573	0.00179	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—SEL1L—Crohn's disease	0.000559	0.00174	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—PTGER4—Crohn's disease	0.000555	0.00173	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—UBE2D1—Crohn's disease	0.00055	0.00171	CbGpPWpGaD
Aprepitant—Hypersensitivity—Prednisone—Crohn's disease	0.000548	0.000996	CcSEcCtD
Aprepitant—Asthenia—Prednisone—Crohn's disease	0.000534	0.00097	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—RIPK2—Crohn's disease	0.000533	0.00166	CbGpPWpGaD
Aprepitant—CYP2C9—Metapathway biotransformation—GPX4—Crohn's disease	0.000528	0.00165	CbGpPWpGaD
Aprepitant—Pruritus—Prednisone—Crohn's disease	0.000527	0.000956	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—IL3—Crohn's disease	0.00052	0.00162	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CCR9—Crohn's disease	0.000511	0.00159	CbGpPWpGaD
Aprepitant—Diarrhoea—Prednisone—Crohn's disease	0.000509	0.000925	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—PTGER4—Crohn's disease	0.000504	0.00157	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—RASGRP1—Crohn's disease	0.000503	0.00157	CbGpPWpGaD
Aprepitant—Dizziness—Prednisone—Crohn's disease	0.000492	0.000894	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—GPR65—Crohn's disease	0.000475	0.00148	CbGpPWpGaD
Aprepitant—Vomiting—Prednisone—Crohn's disease	0.000473	0.000859	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—IL3—Crohn's disease	0.000473	0.00148	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000472	0.00147	CbGpPWpGaD
Aprepitant—Rash—Prednisone—Crohn's disease	0.000469	0.000852	CcSEcCtD
Aprepitant—Dermatitis—Prednisone—Crohn's disease	0.000469	0.000851	CcSEcCtD
Aprepitant—Headache—Prednisone—Crohn's disease	0.000466	0.000847	CcSEcCtD
Aprepitant—TACR1—SIDS Susceptibility Pathways—IL6—Crohn's disease	0.000463	0.00144	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000458	0.00143	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—JAK2—Crohn's disease	0.000456	0.00142	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—SOCS1—Crohn's disease	0.000455	0.00142	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—GPX4—Crohn's disease	0.000451	0.00141	CbGpPWpGaD
Aprepitant—Nausea—Prednisone—Crohn's disease	0.000442	0.000803	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—TYK2—Crohn's disease	0.000434	0.00135	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—IL3—Crohn's disease	0.00043	0.00134	CbGpPWpGaD
Aprepitant—CYP2C19—Arachidonic acid metabolism—PTGS2—Crohn's disease	0.000424	0.00132	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—CXCL8—Crohn's disease	0.000416	0.0013	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—RASGRP1—Crohn's disease	0.000416	0.0013	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—JAK2—Crohn's disease	0.000414	0.00129	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—SMAD3—Crohn's disease	0.000393	0.00123	CbGpPWpGaD
Aprepitant—CYP2C9—Arachidonic acid metabolism—PTGS2—Crohn's disease	0.000387	0.00121	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—CXCL8—Crohn's disease	0.000378	0.00118	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Crohn's disease	0.000368	0.00115	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—IL2RA—Crohn's disease	0.000364	0.00114	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000363	0.00113	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CXCL8—Crohn's disease	0.00036	0.00112	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	0.000358	0.00112	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—Crohn's disease	0.000353	0.0011	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—GPX4—Crohn's disease	0.000348	0.00109	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CCR6—Crohn's disease	0.000338	0.00106	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—IL2RA—Crohn's disease	0.000331	0.00103	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000331	0.00103	CbGpPWpGaD
Aprepitant—CYP1A2—Arachidonic acid metabolism—PTGS2—Crohn's disease	0.00033	0.00103	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Crohn's disease	0.000329	0.00102	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	0.000309	0.000963	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—RBX1—Crohn's disease	0.000306	0.000954	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—IL2RA—Crohn's disease	0.000301	0.000939	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PTGER4—Crohn's disease	0.000298	0.000929	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PLA2G4F—Crohn's disease	0.000289	0.000903	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000283	0.000883	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	0.000282	0.000878	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—UBE2D1—Crohn's disease	0.000268	0.000837	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—RIPK2—Crohn's disease	0.00026	0.000812	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TYK2—Crohn's disease	0.000257	0.0008	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL3—Crohn's disease	0.000254	0.000791	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—MTMR3—Crohn's disease	0.000246	0.000767	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—RASGRP1—Crohn's disease	0.000245	0.000765	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—JAK2—Crohn's disease	0.000245	0.000763	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	0.000241	0.00075	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.000241	0.00075	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Crohn's disease	0.000238	0.000743	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Crohn's disease	0.000238	0.000743	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.000225	0.000703	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CXCL8—Crohn's disease	0.000223	0.000696	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—JAK2—Crohn's disease	0.000223	0.000695	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—SOCS1—Crohn's disease	0.000222	0.000694	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.000219	0.000684	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—IL6—Crohn's disease	0.000212	0.000662	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—TYK2—Crohn's disease	0.000212	0.000661	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PLA2G4F—Crohn's disease	0.000209	0.000652	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.000205	0.000641	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—CXCL8—Crohn's disease	0.000203	0.000634	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—JAK2—Crohn's disease	0.000202	0.000631	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—SMAD3—Crohn's disease	0.000192	0.000599	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—FADS1—Crohn's disease	0.000192	0.000598	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.000187	0.000585	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CXCL8—Crohn's disease	0.000185	0.000576	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—STAT3—Crohn's disease	0.00018	0.00056	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GPX4—Crohn's disease	0.00018	0.00056	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—MTMR3—Crohn's disease	0.000178	0.000555	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL2RA—Crohn's disease	0.000178	0.000554	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.000176	0.000547	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GCKR—Crohn's disease	0.000173	0.000541	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PLA2G4F—Crohn's disease	0.000162	0.000504	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PLA2G4F—Crohn's disease	0.000147	0.00046	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—FADS1—Crohn's disease	0.000139	0.000432	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—MTMR3—Crohn's disease	0.000138	0.000429	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GPX4—Crohn's disease	0.00013	0.000405	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PLA2G4F—Crohn's disease	0.000126	0.000393	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—IL6—Crohn's disease	0.000125	0.000391	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—MTMR3—Crohn's disease	0.000125	0.000391	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GCKR—Crohn's disease	0.000125	0.000391	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TYK2—Crohn's disease	0.000125	0.000391	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—JAK2—Crohn's disease	0.00012	0.000373	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CXCL8—Crohn's disease	0.000109	0.00034	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—MTMR3—Crohn's disease	0.000107	0.000334	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—FADS1—Crohn's disease	0.000107	0.000334	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—IL6—Crohn's disease	0.000104	0.000323	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GPX4—Crohn's disease	0.0001	0.000313	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—FADS1—Crohn's disease	9.77e-05	0.000305	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	9.73e-05	0.000303	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GCKR—Crohn's disease	9.69e-05	0.000302	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GPX4—Crohn's disease	9.15e-05	0.000285	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GCKR—Crohn's disease	8.84e-05	0.000276	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—STAT3—Crohn's disease	8.77e-05	0.000274	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—FADS1—Crohn's disease	8.35e-05	0.00026	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—MTMR3—Crohn's disease	8.27e-05	0.000258	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GPX4—Crohn's disease	7.82e-05	0.000244	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GCKR—Crohn's disease	7.55e-05	0.000235	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	6.93e-05	0.000216	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—FADS1—Crohn's disease	6.44e-05	0.000201	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	6.31e-05	0.000197	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL6—Crohn's disease	6.13e-05	0.000191	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	6.06e-05	0.000189	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GPX4—Crohn's disease	6.03e-05	0.000188	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GCKR—Crohn's disease	5.83e-05	0.000182	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	5.52e-05	0.000172	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ALB—Crohn's disease	5.52e-05	0.000172	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	5.4e-05	0.000168	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PTGS2—Crohn's disease	4.83e-05	0.000151	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	4.72e-05	0.000147	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ALB—Crohn's disease	3.99e-05	0.000124	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PTGS2—Crohn's disease	3.49e-05	0.000109	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ALB—Crohn's disease	3.08e-05	9.62e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ALB—Crohn's disease	2.81e-05	8.77e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PTGS2—Crohn's disease	2.7e-05	8.41e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PTGS2—Crohn's disease	2.46e-05	7.67e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ALB—Crohn's disease	2.4e-05	7.49e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PTGS2—Crohn's disease	2.1e-05	6.56e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ALB—Crohn's disease	1.85e-05	5.78e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PTGS2—Crohn's disease	1.62e-05	5.06e-05	CbGpPWpGaD
